A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Trial Profile

A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD 1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2017

At a glance

  • Drugs REGN 2810 (Primary) ; Carboplatin; Cyclophosphamides; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2017 Preliminary results from patients with advanced cutaneous squamous cell carcinoma (n=26) published in a Regeneron Pharmaceuticals media release.
    • 04 Jun 2017 According to a Regeneron Pharmaceuticals media release, data pooled from two expansion cohorts of patients with advanced cutaneous squamous cell carcinoma (CSCC) from this trial will be presented today at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 02 Jun 2017 Results (n=26; data cut off: 31 Jan 2017) assessing initial safety and efficacy from expansion cohorts presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top